Karyopharm Says 'Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers,' Will Present Updated SIGN Phase 2 Data at ESMO